using glp 1 short term Study: Many Patients Stop Weight Management Drugs Early GLP-1: Long-Term vs. Short-Term? What

This demand stems not just from hype, but from the increasing number of people who are dissatisfied with temporary fixes, chemical-laden products, or invasive interventions

NAD+ is a coenzyme studied in cellular-metabolism and aging research

Aging of cells can cause serious problems not only in terms of aesthetics but also in terms of physical health

In addition to the US FDA approved GLP-1RAs, there are GLP1/glucagon dual agonists (Cotadutide, BI 456906), GIP/GLP1 dual agonists (Tirzepatide, GIP/GLP peptide I and II), GIP/GLP1/glucagon tri-agonists (HM15211, GGG tri-agonist) and GLP1R agonists (Efpeglenatide, Rybelsus) currently in phase 1- III clinical trials for T2D, obesity, and NASH (MASH) treatments (12)

Once we move past the current hype phase and the dust settles, the rules of the road governing typical competitive dynamics of pharmaceutical prescription markets will re-establish themselves in obesity